- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence
In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.
Manual assessments of prostate specific membrane antigen (PSMA) scoring and measures such as standardized uptake value (SUV) mean and maximum SUV (SUVmax) on positron emission tomography (PET) scans can be tedious and are not always accurate, noted Hong Song, M.D., Ph.D., in a recent interview.
With this in mind, Dr. Song and colleagues recently evaluated the combination of aPROMISE software (PYLARIFY AI, Exini Diagnostics AB/Lantheus Holdings), an FDA-cleared deep learning platform for quantitative assessment of PSMA PET/CT images, and piflufostat F 18 (PYLARIFY®, Lantheus Holdings) to assess 69 patients with prostate cancer recurrence and the impact of quantitative measures upon subsequent biochemical progression-free survival.
In some of the findings from the study, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, the researchers noted that higher PSMA-avid total tumor volume (PSMAAttv) and a higher aPSMA score for bone metastases were both associated with shorter biochemical progression-free survival in patients with prostate cancer.
(Editor’s note: For related content, see “Recurrent Prostate Cancer and Low PSA Levels: Can an Emerging PSMA PET Agent Have an Impact?,” “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer” and “Can Pre-Op MRI Staging Help Predict Prostate Cancer Recurrence After a Prostatectomy?”)
“There are quantitative tools now that are readily available to help us have this prognostic evaluation of (patients) who may be at high risk for subsequent progression (of prostate cancer and) should be followed more closely. … There is more information than meets the eye in the scan that we can now quantify and extract,” emphasized Dr. Song, an assistant professor of radiology (nuclear medicine) at Stanford University.
For more insights from Dr. Song, watch the video below.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
